An overview of satavaptan: a selective V2 receptor antagonist
نویسندگان
چکیده
The increasing recognition of the risk of hyponatremia and its public health impact [1–4] has been matched by increasing interest in the new class of drugs, proven to correct hyponatremia, the arginine vasopressin (AVP) V2 receptor antagonists (so-called vaptans). Two vaptans have already been approved for the management of hyponatremia in the USA, and considerable research efforts have been devoted to develop other vaptans. This article details the basic, animal and human studies of the AVP antagonist satavaptan.
منابع مشابه
Global analysis of the effects of the V2 receptor antagonist satavaptan on protein phosphorylation in collecting duct.
Satavaptan (SR121463) is a vasopressin V2 receptor antagonist that has been shown to improve hyponatremia in patients with cirrhosis, congestive heart failure, and syndrome of inappropriate antidiuresis. While known to inhibit adenylyl cyclase-mediated accumulation of intracellular cyclic AMP and potentially recruit β-arrestin in kidney cell lines, very little is known regarding the signaling p...
متن کاملTherapeutic potential of vasopressin-receptor antagonists in heart failure.
Arginine vasopressin (AVP) is a 9-amino acid peptide that is secreted from the posterior pituitary in response to high plasma osmolality and hypotension. AVP has important roles in circulatory and water homoeostasis, which are mediated by oxytocin receptors and by AVP receptor subtypes: V(1a) (mainly vascular), V(1b) (pituitary), and V(2) (renal). Vaptans are orally and intravenously active non...
متن کاملNew topics in vasopressin receptors and approach to novel drugs: preface.
Arginine vasopressin (AVP) is a cyclic nonapeptide that is centrally synthesized in the hypothalamus. Vasopressin has a plethora of biological effects including not only organ regulation but also behavioral ones, which are mediated by the vasopressin-receptor subtypes V1a (vascular), V1b (pituitary) V2 (renal), and oxytocin receptors. Recently, non-peptide vasopressin receptor–selective agonist...
متن کاملSuccessful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist.
The effects of satavaptan (SR121463B), a novel long-acting orally active vasopressin V(2)-receptor antagonist, were investigated in patients with the syndrome of inappropriate antidiuretic hormone secretion (SIADH). In the first part of this randomized, double-blind study, 34 patients first were treated with satavaptan (versus placebo) for up to 5 d and then during 23 d of open-label dosage-adj...
متن کاملSatavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity.
OBJECTIVE Satavaptan, a vasopressin V2 receptor antagonist, has been shown to improve the control of ascites in cirrhosis in short-term phase II studies. The aim of this study was to evaluate the efficacy and safety of satavaptan in three different populations of patients with cirrhosis and ascites. METHODS 1200 patients were included in three randomised double-blind studies comparing satavap...
متن کامل